{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15.2","upperLimit":"23.6","value":"19.4"},{"groupId":"OG001","lowerLimit":"21.4","upperLimit":"27.6","value":"25.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"233"},{"groupId":"OG001","value":"116"}],"units":"Participants"}],"description":"Overall survival (OS) is defined as the number of days from the date of randomization to the date of death (due to any cause). Patients who are still alive were censored on the date of their last available visit or last date known to be alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients randomized to the rucaparib arm.","id":"OG000","title":"Rucaparib"},{"description":"Patients randomized to the chemotherapy arm.","id":"OG001","title":"Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"Intent-to-Treat (ITT) Population - All randomized patients in the treatment part of the study.","reportingStatus":"POSTED","timeFrame":"All patients were followed for survival up to approximately 3.5 years.","title":"Overall Survival (ITT Population)","type":"SECONDARY","unitOfMeasure":"Months"}